New Market Research Report: Sweden Pharmaceuticals & Healthcare Report Q3 2016

Pharmaceutical companies will face an increasingly tough drug pricing environment in Sweden. The government will expand its use of pharmacoeconomic evaluations in order to provide appropriate justification of current expenditures and future investments in public healthcare, impairing the revenue earning opportunities presented by the growing demand for medicines.Headline Expenditure ProjectionsPharmaceuticals: SEK39.50bn (USD4.68bn) in 2015 to SEK39.67bn (USD4.66bn) in 2016; +0.43% in local currency terms and -0.4% in US dollar terms.
Healthcare: SEK376.25bn (USD44.61bn) in 2015 to SEK386.01bn (USD45.39bn) in2016; +2.6% in local currency terms and 1.6% in US dollar terms.Risk/Reward IndexIn BMI's Q316 Risk/Rewards Index, Sweden ranks eighth in the region. Factors such as the country's high per capita incomes and strong regulatory foundations will continue to promote per capita spending on pharmaceuticals and healthcare in general. However, the downward pressure on pharmaceutical prices will continue to be acutely felt in this small market of fewer than 10mn people.Latest UpdatesAccording to the Swedish Association of the Pharmaceutical Industry (LIF), Sweden's total expenditure for medicines has during the past decade increased much more slowly than health care costs in general.According to LIF, Life expectancy in Sweden is increasing by one year every six years. One-third of this increase is attributed to new medical treatments.According to the International Diabetes Federation, there were 446,900 cases of diabetes in Sweden in 2015.BMI Economic ViewThe Swedish economy is in a 'sweet spot', with real GDP growth soaring and inflation remaining low. However, the ultra-easy monetary policy that has underpinned the recent expansion is building up problems for the future, and will put the economy at risk of a shock beyond 2016.BMI Political ViewSwedish politics will continue to be dominated by the issue of mass immigration. However, the mainstream parties' increasingly harsh stance on asylum seekers is pushing the populist far-right Sweden Democrats further to the margins, and makes it increasingly likely that the opposition centre-right Alliance will win the 2018 parliamentary elections.

Full Report Details at
- http://www.fastmr.com/prod/1172872_sweden_pharmaceuticals.aspx?afid=301

The Sweden Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Sweden Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Sweden pharmaceutical and healthcare industry.

Key Benefits

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Brazil Pharmaceuticals & Healthcare Report Q3 2016
- Czech Republic Pharmaceuticals & Healthcare Report Q3 2016
- Bahrain Pharmaceuticals & Healthcare Report Q3 2016
- China Pharmaceuticals & Healthcare Report Q3 2016
- Egypt Pharmaceuticals & Healthcare Report Q3 2016